Sumitomo Chemical Group reported consolidated sales revenue of ¥1,642.6 billion, decrease of ¥8.1 billion year on year for the nine months ended December 31, 2020.

The core operating income of ¥107.0 billion, operating income of ¥116.6 billion and net income attributable to owners of the parent of ¥21.9 billion; all lower than the results from the same period of the previous year.

The revenue from Petrochemicals and Plastics sales declined by ¥109.9 billion from the same period of the previous year to ¥408.4 billion. Also, the core operating income suffered a loss of ¥27.9 billion, declined by ¥55.2 billion from the same period of the previous year.

Energy & Functional Materials sales revenue dropped by ¥15.3 billion from the same period of the previous year to ¥175.4 billion, and core operating income declined by ¥2.1 billion from the same period of the previous year to ¥15.6 billion.

IT-related Chemicals sales revenue increased by ¥19.3 billion from the same period of the previous year to ¥324.3 billion and core operating income increased by ¥13.2 billion from the same period of the previous year to ¥31.8 billion.

Health and Crop Sciences sales revenue increased by ¥63.9 billion from the same period of the previous year to ¥282.4 billion. Backed by the improved margins of methionine and increased international shipment of crop protection products, core operating income recovered from a year earlier loss to ¥12.2 billion, an increase of ¥25.8 billion from the same period of the previous year.

Pharmaceuticals sales increased in Japan, driven by Equa and EquMet (for type II diabetes mellitus) launched in the previous fiscal year. In North America, sales of Latuda (atypical antipsychotic agent) increased. As a result, sales revenue increased by ¥35.3 billion from the same period of the previous year to ¥417.5 billion. Core operating income increased by ¥7.2 billion from the same period of the previous year to ¥74.7 billion.

Sales revenue of other businesses declined by ¥1.5 billion from the same period of the previous year to ¥34.6 billion and core operating income increased by ¥2.4 billion from the same period of the previous year to ¥10.3 billion.